GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Azitra Inc (AMEX:AZTR) » Definitions » Operating Margin %

Azitra (Azitra) Operating Margin % : -2,866.67% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Azitra Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Azitra's Operating Income for the three months ended in Dec. 2023 was $-2.58 Mil. Azitra's Revenue for the three months ended in Dec. 2023 was $0.09 Mil. Therefore, Azitra's Operating Margin % for the quarter that ended in Dec. 2023 was -2,866.67%.

The historical rank and industry rank for Azitra's Operating Margin % or its related term are showing as below:

AZTR' s Operating Margin % Range Over the Past 10 Years
Min: -8382.73   Med: -3328.87   Max: -1110.2
Current: -1110.64


AZTR's Operating Margin % is ranked worse than
74.32% of 1028 companies
in the Biotechnology industry
Industry Median: -171.86 vs AZTR: -1110.64

Azitra's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Azitra's Operating Income for the three months ended in Dec. 2023 was $-2.58 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.62 Mil.


Azitra Operating Margin % Historical Data

The historical data trend for Azitra's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azitra Operating Margin % Chart

Azitra Annual Data
Trend Dec21 Dec22 Dec23
Operating Margin %
-8,382.73 -3,328.87 -1,110.20

Azitra Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only -8,703.23 -1,380.53 -863.37 -641.16 -2,866.67

Competitive Comparison of Azitra's Operating Margin %

For the Biotechnology subindustry, Azitra's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azitra's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Azitra's Operating Margin % falls into.



Azitra Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Azitra's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-7.616 / 0.686
=-1,110.20 %

Azitra's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-2.58 / 0.09
=-2,866.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Azitra  (AMEX:AZTR) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Azitra Operating Margin % Related Terms

Thank you for viewing the detailed overview of Azitra's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Azitra (Azitra) Business Description

Traded in Other Exchanges
N/A
Address
21 Business Park Drive, Branford, CT, USA, 06405
Anitra Inc is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Executives
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Andrew Mcclary director 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Aktiengesellschaft Bayer 10 percent owner BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Norm Staskey officer: Chief Financial Officer 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Bios Azitra Co-invest I, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bayer Us Holding Lp 10 percent owner 100 BAYER BOULEVARD, WHIPPANY NJ 07981
Bayer Healthcare Llc 10 percent owner
Francisco D. Salva director, officer: President and CEO 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Travis Whitfill director, officer: Chief Operating Officer C/O IN8BIO,INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107